VALPROATE-AFT sodium valproate 1000 mg/10 ml solution for intravenous infusion or injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

valproate-aft sodium valproate 1000 mg/10 ml solution for intravenous infusion or injection vial

aft pharmaceuticals pty ltd - sodium valproate, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: water for injections; nitrogen; monobasic potassium phosphate; dibasic sodium phosphate dodecahydrate - valproate-aft is used for the treatment of patients with epilepsy or mania, who would normally be maintained on oral sodium valproate, and for whom oral therapy is temporarily not possible

NIMODIPINE JUNO nimodipine 10 mg/50 mL concentrated intravenous infusion solution vial Australia - English - Department of Health (Therapeutic Goods Administration)

nimodipine juno nimodipine 10 mg/50 ml concentrated intravenous infusion solution vial

juno pharmaceuticals pty ltd - nimodipine, quantity: 10 mg - injection, intravenous infusion - excipient ingredients: citric acid; sodium citrate dihydrate; water for injections; ethanol; macrogol 400 - prophylaxis and treatment of ischaemic neurological deficits caused by cerebral vasospasm after subarachnoid haemorrhage following ruptured intracranial aneurysm, in patients who are in good neurological condition post-ictus, e.g., hunt and hess grades i-iii (see section 5.1 pharmacodynamic properties).

ULTOMIRIS ravulizumab rch 300 mg in 3 mL (100 mg/mL) concentrated solution for injection by intravenous infusion vial Australia - English - Department of Health (Therapeutic Goods Administration)

ultomiris ravulizumab rch 300 mg in 3 ml (100 mg/ml) concentrated solution for injection by intravenous infusion vial

alexion pharmaceuticals australasia pty ltd - ravulizumab, quantity: 100 mg/ml - injection, intravenous infusion - excipient ingredients: monobasic sodium phosphate; dibasic sodium phosphate; polysorbate 80; arginine; sucrose; water for injections - ultomiris is indicated:,? for the treatment of patients with paroxysmal nocturnal haemoglobinuria (pnh),? for the treatment of patients with atypical haemolytic uraemic syndrome (ahus),? as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti-acetylcholine receptor (achr) antibody-positive.,? for the treatment of adult patients with neuromyelitis optica spectrum disorder (nmosd) who are anti-aquaporin 4 (aqp4) antibody-positive.,ultomiris is not intended for the acute treatment of a nmosd relapse.

TRINTELLIX- vortioxetine tablet, film coated United States - English - NLM (National Library of Medicine)

trintellix- vortioxetine tablet, film coated

takeda pharmaceuticals america, inc. - vortioxetine hydrobromide (unii: tks641koay) (vortioxetine - unii:3o2k1s3wqv) - vortioxetine 5 mg - trintellix is indicated for the treatment of major depressive disorder (mdd) in adults. - hypersensitivity to vortioxetine or any component of the formulation. hypersensitivity reactions including anaphylaxis, angioedema, and urticaria have been reported in patients treated with trintellix [see adverse reactions (6.2)] . - the use of maois intended to treat psychiatric disorders with trintellix or within 21 days of stopping treatment with trintellix is contraindicated because of an increased risk of serotonin syndrome. the use of trintellix within 14 days of stopping an maoi intended to treat psychiatric disorders is also contraindicated [see dosage and administration (2.4), warnings and precautions (5.2)] . starting trintellix in a patient who is being treated with maois such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome [see warnings and precautions (5.2)] . pregnancy exposure registry there is a pregnancy exposure registry that monit

DEXTROSE 5% IN 0.225% SOD. CHLORIDE INF Intravenous infusion Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

dextrose 5% in 0.225% sod. chloride inf intravenous infusion

pharmaceutical solution industries (psi), saudi arabia - dextrose,sodium chloride - intravenous infusion - 5,0.225 %

DEXTROSE 5% IN 0.225% SOD. CHLORIDE INF Intravenous infusion Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

dextrose 5% in 0.225% sod. chloride inf intravenous infusion

pharmaceutical solution industries (psi), saudi arabia - dextrose,sodium chloride - intravenous infusion - 5,0.225 %

DEXTROSE 5% IN RINGER SOLUTION Intravenous infusion Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

dextrose 5% in ringer solution intravenous infusion

pharmaceutical solution industries (psi), saudi arabia - dextrose, ringer(s) solution - intravenous infusion - 5 %

DEXTROSE 5% INFUSION Intravenous infusion Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

dextrose 5% infusion intravenous infusion

pharmaceutical solution industries (psi), saudi arabia - dextrose - intravenous infusion - 5 %

DEXTROSE 50% Intravenous infusion Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

dextrose 50% intravenous infusion

pharmaceutical solution industries (psi), saudi arabia - dextrose - intravenous infusion - 50 %

DEXTROSE 50% Intravenous infusion Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

dextrose 50% intravenous infusion

pharmaceutical solution industries (psi), saudi arabia - dextrose - intravenous infusion - 50 %